DOI: 10.1055/s-00000030

Der Klinikarzt

References

Di Leo A, Johnston S, Lee KS. et al.
Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet Oncol 2018;
19: 87-100

Download Bibliographical Data

Search in:
Access:
Access: